Key inclusion criteria:

          -  Histologically or cytologically confirmed Stage II, IIIA, or select IIIB (T3N2 only)
             NSCLC of squamous or non-squamous histology

          -  Eligible for R0 resection with curative intent at the time of screening

          -  Adequate pulmonary function to be eligible for surgical resection with curative intent

          -  Eligible to receive a platinum-based chemotherapy regimen

          -  Measurable disease, as assessed by the investigator per Response Evaluation Criteria
             in Solid Tumors (RECIST) v1.1

          -  Availability of a representative tumor specimen that is suitable for determination of
             PD-L1 status

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

          -  Normal life expectancy, excluding lung cancer mortality risk

          -  Adequate hematologic and end-organ function

          -  Negative human immunodeficiency virus (HIV) test at screening

          -  Negative serology for active hepatitis B virus (HBV) and active hepatitis C virus
             (HCV) at screening

        Key Exclusion Criteria:

          -  NSCLC with histology of large cell neuroendocrine carcinoma, sarcomatoid carcinoma, or
             NSCLC not otherwise specified

          -  Small cell lung cancer (SCLC) histology or NSCLC with any component of SCLC

          -  Any prior therapy for lung cancer

          -  Active or history of autoimmune disease or immune deficiency

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest computed tomography (CT) scan

          -  Active tuberculosis

          -  Significant cardiovascular disease

          -  NSCLC with an activating EGFR mutation or ALK fusion oncogene

          -  Known c-ros oncogene 1 (ROS1) rearrangement

          -  History of malignancy other than NSCLC within 5 years prior to screening, with the
             exception of malignancies with negligible risk of metastasis or death

          -  Severe infection within 4 weeks prior to initiation of study treatment or any active
             infection that, in the opinion of the investigator, could impact patient safety

          -  Prior treatment with CD127 agonists or immune checkpoint blockade therapies, including
             anti-CTLA-4, anti-PD-1, anti-TIGIT, and anti-PD-L1 therapeutic antibodies

          -  Treatment with systemic immunostimulatory agents

          -  Treatment with systemic immunosuppressive medication

          -  Pregnancy or breastfeeding